Inflammatory bowel disease (IBD) is associated with increased intestinal extrachromosomal circular DNA: an emerging biomarker for IBD type and activity - Scorecard - MDSpire
Advertisement
Inflammatory bowel disease (IBD) is associated with increased intestinal extrachromosomal circular DNA: an emerging biomarker for IBD type and activity
Clinical Scorecard: Association of Increased Intestinal Extrachromosomal Circular DNA with Inflammatory Bowel Disease: A Potential Biomarker for Disease Type and Activity
At a Glance
Category
Detail
Condition
Inflammatory Bowel Disease (IBD), including Ulcerative Colitis (UC) and Crohn’s Disease (CD)
Key Mechanisms
Increased intestinal extrachromosomal circular DNA (eccDNA) production associated with chronic intestinal inflammation and DNA damage
Target Population
Adult patients with histologically confirmed IBD (UC or CD)
Care Setting
Gastroenterology clinical and research settings involving intestinal biopsy analysis
Key Highlights
IBD patients exhibit significantly higher levels of intestinal eccDNA compared to healthy controls.
Active ulcerative colitis shows increased eccDNA production compared to remission; Crohn’s disease shows elevated eccDNA but less distinction between active and inactive states.
Specific eccDNAs containing gene fragments (e.g., NRG1, ZPMF2) are enriched in active IBD and may serve as novel biomarkers.
Guideline-Based Recommendations
Diagnosis
Diagnosis of IBD remains based on clinical assessment and detection of intestinal inflammation via biopsy.
Consideration of eccDNA profiling in intestinal biopsies as a potential adjunct biomarker for disease activity and type.
Management
Current therapies have limited response rates; identification of eccDNA biomarkers may guide personalized treatment strategies in the future.
Monitoring & Follow-up
Monitoring eccDNA levels in intestinal tissue may help assess disease activity, especially in ulcerative colitis.
Further research needed to validate eccDNA as a tool for monitoring disease progression and response.
Risks
Chronic inflammation in IBD increases DNA damage and oxidative stress, potentially contributing to disease progression and cancer risk.
Elevated eccDNA may reflect underlying genomic instability associated with inflammation.
Patient & Prescribing Data
Adult patients with confirmed ulcerative colitis or Crohn’s disease undergoing intestinal biopsy.
Approximately 40%-60% of IBD patients respond to therapy; eccDNA biomarkers may help predict therapy response and disease course.
Clinical Best Practices
Use comprehensive clinical and histological assessment for IBD diagnosis.
Incorporate emerging molecular biomarkers such as eccDNA profiling to enhance disease characterization.
Recognize the heterogeneity of IBD and the need for personalized therapeutic approaches.
Monitor patients closely for disease activity and potential progression to colitis-associated cancer.
